ロード中...
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine
OBJECTIVE: To compare the cancer risk of cladribine and other disease-modifying drugs (DMDs) in trials of people with relapsing multiple sclerosis (pwRMS). METHODS: Meta-analysis of phase III trials of licensed DMDs for pwRMS and a phase III trial of cladribine (CLARITY). Cancer rates were compared...
保存先:
| 出版年: | Neurol Neuroimmunol Neuroinflamm |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Lippincott Williams & Wilkins
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4592538/ https://ncbi.nlm.nih.gov/pubmed/26468472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000158 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|